Long-term systemic angiotensin II type 1 receptor blockade regulates mRNA expression of dorsomedial medulla renin-angiotensin system components. Physiol Genomics 43: 829 -835, 2011. First published May 3, 2011 doi:10.1152/physiolgenomics.00167.2010 rats, renin-angiotensin system (RAS) blockade for 1 yr with the angiotensin II type 1 (AT1) receptor blocker L-158,809 prevents age-related impairments in metabolic function, similar to transgenic rats with low glial angiotensinogen (Aogen). Brain RAS regulation may contribute to the benefits of long-term systemic AT1 antagonism. We assessed the mRNA of RAS components in the dorsomedial medulla of F344 rats at 3 (young; n ϭ 8) or 15 mo of age (old; n ϭ 7) and in rats treated from 3 to 15 mo of age with 20 mg/l of the AT1 receptor antagonist L-158,809 (OldϩL; n ϭ 6). Aogen and renin mRNA were lower in the young compared with old group. Angiotensin-converting enzyme (ACE) mRNA was lower in the old and OldϩL compared with the young group. ACE2 and neprilysin expression were significantly higher in OldϩL compared with young or old rats. AT1b, AT2, and Mas receptor mRNA were higher with treatment. Leptin receptor mRNA was lower in the old rats and this was prevented by L-158,809 treatment. Dual-specificity phosphatase 1 (DUSP1) mRNA was highest in the OldϩL group. Aggregate correlate summation revealed a positive relationship for Mas receptor mRNA with food intake. The findings provide evidence for regulation of dorsomedial medullary renin and Aogen mRNA during aging. Long-term AT1 receptor blockade increases the mRNA of the enzymes ACE2 and neprilysin and the MAS receptor, which could potentially shift the balance from ANG II to ANG-(1-7) and prevent age-related declines in the leptin receptor and its signaling pathway.angiotensinogen; Fischer 344 rats; leptin; aggregate correlate summation SYSTEMIC BLOCKADE OF the renin-angiotensin system (RAS) with angiotensin II type 1 (AT 1 ) receptor blockers or angiotensinconverting enzyme (ACE) inhibitors provides beneficial effects outside of the classic hemodynamic actions. RAS blockade improves many components of aging and reduces the onset of the metabolic syndrome and Type 2 diabetes (1,8,17,43). However, the precise mechanisms underlying the beneficial effects are not entirely known. During aging, there is a decline in the circulating (systemic) RAS, including angiotensin (ANG)-(1-7) (30), suggesting that the beneficial actions of RAS blockade are partly due to the suppression of ANG II in tissues. Many tissues and organs contain their own local RAS, including the kidney, heart, vessels, adrenal gland, pancreas, and brain (4, 25). Increased brain ANG II activates sympathetic outflow, inhibits the baroreflex, stimulates thirst, and contributes to neurogenic hypertension (25,36, 38). In rats with chronic renal failure, components of the brain RAS are upregulated, resulting in sympathetic overactivity and hypertension (29). Transgenic mice with increased production of brain ANG II developed hypertension and an increase in salt ...